Background: Prediabetes in individuals with obesity is a high-risk state for progression to type 2 diabetes mellitus (T2DM). Circulating microRNAs (miRNAs) have emerged as promising minimally invasive biomarkers for early detection. However, their diagnostic performance and consistency across studies remain unclear. Objectives: To evaluate circulating miRNAs as potential biomarkers for prediabetes in obese populations. Methods: A systematic search of PubMed, MEDLINE, Scopus, and EBSCOhost was conducted (September 2012–September 2025) without language restrictions. Eligible studies included observational, clinical, and translational research assessing circulating miRNAs in plasma, serum, whole blood, or exosomes using qRT-PCR, ddPCR, microarray, or next-generation sequencing. Two reviewers independently screened studies and extracted data using a piloted form. Extracted information was synthesized qualitatively; diagnostic performance measures and reported miRNAs were tabulated. Results: Nine circulating microRNAs (miR-27, miR-30a, miR-34a, miR-93, miR-122, miR-126, miR-146a, miR-192, and miR-193b) were consistently dysregulated in obese individuals with prediabetes across thirteen included human studies. These miRNAs were linked to key pathogenic mechanisms including chronic inflammation, insulin resistance, β-cell dysfunction, and altered adipokine signaling. Notably, inflammation-associated miRNAs (miR-27, miR-34a, miR-146a) reflected the transition from metabolically healthy to unhealthy obesity, while β-cell–related miRNAs (miR-30a, miR-126) indicated early impairment of insulin secretion. Among detection platforms, qRT-PCR remained the most sensitive and specific method for miRNA quantification, whereas microarray and next-generation sequencing provided broader profiling capability but with higher cost and complexity. Conclusions: Circulating miRNAs demonstrate promise as diagnostic biomarkers for prediabetes in obesity. However, these findings are limited by methodological variability. Thus, large-scale and standardized studies are required to validate their clinical utility.